(Q46003075)

English

Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19458624

Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19458624

author name string

P Palatini

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19458624

W Jung

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19458624

E Shlyakhto

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19458624

J Botha

4

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19458624

C Bush

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19458624

D L Keefe

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19458624

publication date

21 May 2009

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19458624

Journal of Human Hypertension

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19458624

24

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19458624

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19458624

93-103

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19458624

https://scigraph.springernature.com/pub.10.1038/jhh.2009.38

0 references

Medication adherence and persistence as the cornerstone of effective antihypertensive therapy

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.38

7 January 2021

based on heuristic

inferred from DOI database lookup

Awareness, knowledge, and attitudes of older americans about high blood pressure: implications for health care policy, education, and research

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.38

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.38

7 January 2021

based on heuristic

inferred from DOI database lookup

Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories.

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.38

7 January 2021

based on heuristic

inferred from DOI database lookup

Aliskiren: a review of its use in the management of hypertension

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.38

7 January 2021

based on heuristic

inferred from DOI database lookup

Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.38

7 January 2021

based on heuristic

inferred from DOI database lookup

Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.38

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.38

7 January 2021

based on heuristic

inferred from DOI database lookup

Persistence of antihypertensive efficacy after missed doses: comparison of amlodipine and nifedipine gastrointestinal therapeutic system

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.38

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of one or two missed doses on the duration of action of combined perindopril and indapamide

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.38

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.38

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesar

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.38

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of single versus twice daily dosing of ramipril by ambulatory blood pressure monitoring in patients similar to those included in the HOPE study

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.38

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.38

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.38

7 January 2021

based on heuristic

inferred from DOI database lookup

Structure-based design of aliskiren, a novel orally effective renin inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.38

7 January 2021

based on heuristic

inferred from DOI database lookup

The renin rise with aliskiren: it's simply stoichiometry

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.38

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/JHH.2009.38

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19458624

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19458624

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46003075&oldid=1456498498"